- Home
- AHG vs PROK Comparison
AHG vs PROK Comparison
Compare AHG & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- PROK
- Stock Information
- Founded
- AHG 2013
- PROK 2015
- Country
- AHG China
- PROK United States
- Employees
- AHG N/A
- PROK N/A
- Industry
- AHG Business Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AHG Consumer Discretionary
- PROK Health Care
- Exchange
- AHG Nasdaq
- PROK Nasdaq
- Market Cap
- AHG 245.7M
- PROK 220.6M
- IPO Year
- AHG N/A
- PROK N/A
- Fundamental
- Price
- AHG $0.83
- PROK $2.03
- Analyst Decision
- AHG
- PROK Buy
- Analyst Count
- AHG 0
- PROK 5
- Target Price
- AHG N/A
- PROK $4.50
- AVG Volume (30 Days)
- AHG 16.3K
- PROK 392.4K
- Earning Date
- AHG 11-22-2024
- PROK 11-19-2024
- Dividend Yield
- AHG N/A
- PROK N/A
- EPS Growth
- AHG N/A
- PROK N/A
- EPS
- AHG N/A
- PROK N/A
- Revenue
- AHG $2,414,338.00
- PROK N/A
- Revenue This Year
- AHG N/A
- PROK N/A
- Revenue Next Year
- AHG N/A
- PROK N/A
- P/E Ratio
- AHG N/A
- PROK N/A
- Revenue Growth
- AHG N/A
- PROK N/A
- 52 Week Low
- AHG $0.53
- PROK $1.12
- 52 Week High
- AHG $2.90
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- AHG 42.44
- PROK 64.25
- Support Level
- AHG $0.90
- PROK $1.49
- Resistance Level
- AHG $0.95
- PROK $1.83
- Average True Range (ATR)
- AHG 0.07
- PROK 0.12
- MACD
- AHG -0.00
- PROK 0.06
- Stochastic Oscillator
- AHG 11.17
- PROK 100.00
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.